<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647423</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-3.091</org_study_id>
    <nct_id>NCT03647423</nct_id>
  </id_info>
  <brief_title>QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.</brief_title>
  <official_title>QUILT-3.091 NANT Chordoma Vaccine: A Randomized Phase 1b/2 Trial of the NANT Chordoma Vaccine vs. Radiation in Subjects With Unresectable Chordoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      QUILT 3.091 Chordoma Vaccine: Phase 1B/2 NANT Chordoma Vaccine vs Radiation in Subjects with&#xD;
      Unresectable Chordoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NANT Chordoma Vaccine regimen will be administered in 2 phases, an induction and a&#xD;
      maintenance phase.&#xD;
&#xD;
      Subjects will continue induction treatment for up to 1 year. Those who have a confirmed&#xD;
      complete response (CR) in the induction phase will enter the maintenance phase of the study.&#xD;
      Subjects who experience ongoing stable disease (SD) or an ongoing partial response (PR) at 1&#xD;
      year may enter the maintenance phase at the Investigator's and Sponsor's discretion. Subjects&#xD;
      may remain in the maintenance phase of the study for up to 1 year.&#xD;
&#xD;
      In the randomized component of the phase 2 portion of the study, the control arm will be&#xD;
      treated with radiation according to established SoC protocols as determined by the&#xD;
      Investigator.&#xD;
&#xD;
      In the phase 2 single-arm component of the study, subjects will be enrolled in the first&#xD;
      stage of Simon's two-stage optimal design. If the study proceeds to the second stage of&#xD;
      Simon's two-stage optimal design, additional subjects will be enrolled in the second stage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Trial not initiated&#xD;
  </why_stopped>
  <start_date type="Anticipated">August 31, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Chordoma Vaccine: A randomized phase 1b/2 trial of the NANT chordoma vaccine vs. radiation in subjects with unresectable chordoma.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.</measure>
    <time_frame>9 weeks</time_frame>
    <description>Phase 1b primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) by RECIST v1.1</measure>
    <time_frame>1 years</time_frame>
    <description>Phase 2 primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate by RECIST v1.1</measure>
    <time_frame>9 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate by irRC</measure>
    <time_frame>9 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) by RECIST v1.1</measure>
    <time_frame>9 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) by irRC</measure>
    <time_frame>9 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>9 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate by RECIST v1.1 and irRC.</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months) by RECIST v1.1 and irRC.</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes of Chordoma cancer symptoms</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 1b secondary endpoint (by RECIST v1.1 and irRC and FACT-Hep questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) by irRC</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate by RECIST 1.1</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate by irRC</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response by RECIST and irRC</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months) by RECIST and irRC.</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes of Chordoma cancer</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint by (RECIST v1.1 and irRC and FACT-Hep questionnaire)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chordoma</condition>
  <condition>Unresectable Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>NANT Chordoma Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab, cyclophosphamide, SBRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled Arm - Radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SBRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldoxorubicin Hydrochloride</intervention_name>
    <description>Aldoxorubicin Hydrochloride HCI</description>
    <arm_group_label>NANT Chordoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>Recombinant human super agonist interleukin-15 (IL-15) complex</description>
    <arm_group_label>NANT Chordoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-051</intervention_name>
    <description>Ad5 [E1-, E2b-]-Brachyury</description>
    <arm_group_label>NANT Chordoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-061</intervention_name>
    <description>Ad5 [E1-, E2b-]-mucin 1 [MUC1]</description>
    <arm_group_label>NANT Chordoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6301</intervention_name>
    <description>Brachyury yeast</description>
    <arm_group_label>NANT Chordoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haNK</intervention_name>
    <description>haNK™, NK-92 [CD16.158V, ER IL-2]</description>
    <arm_group_label>NANT Chordoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>injection</description>
    <arm_group_label>NANT Chordoma Vaccine</arm_group_label>
    <other_name>BAVENCIO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Injection</description>
    <arm_group_label>NANT Chordoma Vaccine</arm_group_label>
    <other_name>ERBITUX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Capsules</description>
    <arm_group_label>NANT Chordoma Vaccine</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Stereotactic body radiation therapy</description>
    <arm_group_label>Controlled Arm - Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             IRB or Independent Ethics Committee (IEC) guidelines.&#xD;
&#xD;
          3. Histologically-confirmed recurrent or unresectable chordoma that would require&#xD;
             radiation as a primary means for treatment.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          5. Have at least 1 measurable lesion of ≥ 1.0 cm.&#xD;
&#xD;
          6. Must have a recent formalin-fixed, paraffin-embedded (FFPE) tumor biopsy specimen&#xD;
             following the conclusion of the most recent anticancer treatment and be willing to&#xD;
             release the specimen for prospective and exploratory tumor molecular profiling. If an&#xD;
             historic specimen is not available, the subject must be willing to undergo a biopsy&#xD;
             during the screening period, if considered safe by the Investigator. If safety&#xD;
             concerns preclude collection of a biopsy during the screening period, a tumor biopsy&#xD;
             specimen collected prior to the conclusion of the most recent anticancer treatment may&#xD;
             be used.&#xD;
&#xD;
          7. Must be willing to provide blood samples prior to the start of treatment on this study&#xD;
             for tumor molecular profiling and exploratory analyses.&#xD;
&#xD;
          8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of&#xD;
             treatment for exploratory analyses, if considered safe by the Investigator.&#xD;
&#xD;
          9. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
         10. Agreement to practice effective contraception for female subjects of child-bearing&#xD;
             potential and non-sterile males. Female subjects of child-bearing potential must agree&#xD;
             to use effective contraception for up to 1 year after completion of therapy, and non-&#xD;
             sterile male subjects must agree to use a condom for up to 4 months after treatment.&#xD;
             Effective contraception includes surgical sterilization (eg, vasectomy, tubal&#xD;
             ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide,&#xD;
             intrauterine devices (IUDs), and abstinence.&#xD;
&#xD;
        Randomized component only - 11. Must be able to be classified into at least 1 of the below&#xD;
        3 categories: i. Recurred within 6 months after treatment, ii. Have metastatic disease,&#xD;
        iii. Meet ≥ 4 of the histopathologic and immunohistochemical criteria: • Poorly&#xD;
        differentiated histopathologic sub type, • Mitotic figures ≥ 3, • Apoptosis present. •&#xD;
        Prominent nucleoli present, • Necrosis present, • Ki67 ≥ 6%, • p53 ≥ 25%&#xD;
&#xD;
        Single-arm component only 12. Must have progressed on or after radiation monotherapy in the&#xD;
        randomized portion of the study OR been ineligible for the randomized portion but had&#xD;
        progressed or experienced unacceptable toxicity on SoC prior to enrollment on the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious uncontrolled concomitant disease that would contraindicate the use of the&#xD;
             investigational drug used in this study or that would put the subject at high risk for&#xD;
             treatment-related complications.&#xD;
&#xD;
          2. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis,Addison's&#xD;
             disease, or autoimmune disease associated with lymphoma).&#xD;
&#xD;
          3. History of organ transplant requiring immunosuppression.&#xD;
&#xD;
          4. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
&#xD;
          5. Inadequate organ function, evidenced by the following laboratory results: a. Absolute&#xD;
             neutrophil count &lt; 1,000 cells/mm^3, b. Uncorrectable grade 3 anemia (hemoglobin &lt; 8&#xD;
             g/dL), c. Platelet count &lt; 75,000 cells/mm^3, d. Total bilirubin greater than the&#xD;
             upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome), e.&#xD;
             Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) &gt; 2.5&#xD;
             × ULN (&gt; 5 × ULN in subjects with liver metastases), f. Alkaline phosphatase levels &gt;&#xD;
             2.5 × ULN (&gt; 5 × ULN in subjects with liver metastases, or &gt;10 × ULN in subjects with&#xD;
             bone metastases), g. Serum creatinine &gt; 2.0 mg/dL or 177 μmol/L, h. Serum anion gap &gt;&#xD;
             16 mEq/L or arterial blood with pH &lt; 7.3.&#xD;
&#xD;
          6. Uncontrolled hypertension (systolic &gt; 160 mm Hg and/or diastolic &gt; 110 mm Hg) or&#xD;
             clinically significant (ie, active) cardiovascular disease, cerebrovascular&#xD;
             accident/stroke, or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; congestive heart failure of New York Heart Association&#xD;
             grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with&#xD;
             uncontrolled hypertension should be medically managed on a stable regimen to control&#xD;
             hypertension prior to study entry.&#xD;
&#xD;
          7. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection&#xD;
             fraction (LVEF) 10% below the institution's lower limit of predicted normal.&#xD;
&#xD;
          8. Dyspnea at rest due to complications of advanced malignancy or other disease requiring&#xD;
             continuous oxygen therapy.&#xD;
&#xD;
          9. Positive results of screening test for human immunodeficiency virus (HIV).&#xD;
&#xD;
         10. Current chronic daily treatment (continuous for &gt; 3 months) with systemic&#xD;
             corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone),&#xD;
             excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic&#xD;
             reaction or anaphylaxis in subjects who have known contrast allergies is allowed.&#xD;
&#xD;
         11. Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
         12. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug&#xD;
             reaction with any of the study medications.&#xD;
&#xD;
         13. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including&#xD;
             ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone,&#xD;
             nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit&#xD;
             products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin,&#xD;
             rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study&#xD;
             day 1.&#xD;
&#xD;
         14. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8&#xD;
             inducer (rifampin) within 14 days before study day 1.&#xD;
&#xD;
         15. Participation in an investigational drug study or history of receiving any&#xD;
             investigational treatment within 30 days prior to screening for this study, except for&#xD;
             testosterone- lowering therapy in men with prostate cancer.&#xD;
&#xD;
         16. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
         17. Concurrent participation in any interventional clinical trial.&#xD;
&#xD;
         18. Pregnant and nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

